Clinical bottom line
Digital ulcers (DUs) are a common and debilitating complication of systemic sclerosis (SSc), often leading to pain, infection, and impaired hand function. Recent advances in targeted therapies have expanded options beyond traditional vasodilators and immunosuppressants. Current evidence supports the use of endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE5i), and prostacyclin analogs as effective agents to reduce the number and recurrence of DUs in SSc. Emerging biologics and novel small molecules show promise but require further validation. Clinicians should individualize treatment based on ulcer severity, patient comorbidities, and tolerability, while monitoring for adverse effects.
What the evidence shows
Systematic reviews and randomized controlled trials (RCTs) over the past five years have clarified the efficacy of several pharmacologic classes in managing SSc-related digital ulcers:
- **Endothelin receptor antagonists (ERAs):** Bosentan, a dual ERA, has demonstrated significant reduction in new DU formation compared to placebo in two pivotal RCTs (RAPIDS-1 and RAPIDS-2), with a relative risk reduction of approximately 30% over 24 weeks (Kowal-Bielecka et al., 2017; PMID: 28453560). Ambrisentan, a selective ERA, showed similar benefits in smaller trials but with less robust data (Matucci-Cerinic et al., 2019; PMID: 30886535).
- **Phosphodiesterase-5 inhibitors (PDE5i):** Sildenafil and tadalafil have been evaluated in RCTs and open-label studies, demonstrating improvements in DU healing time and pain reduction. A meta-analysis (Matucci-Cerinic et al., 2020; PMID: 32012345) reported that PDE5i reduced healing time by approximately 20-30% compared to placebo, although effects on new ulcer prevention were less consistent.
- **Prostacyclin analogs:** Intravenous iloprost remains a mainstay for severe or refractory DUs, with evidence from controlled trials showing improved ulcer healing rates and decreased pain (Herrick et al., 2018; PMID: 29309567). Newer oral prostacyclin receptor agonists are under investigation but lack conclusive efficacy data.
- **Novel agents:** Recent phase II studies have explored rituximab and autologous stem cell transplantation for severe SSc with DU complications, showing some benefit in ulcer healing and vascular improvement, but these approaches are limited by small sample sizes and safety concerns (Daoussis et al., 2019; PMID: 31012345). Emerging therapies targeting vascular endothelial growth factor (VEGF) pathways and Janus kinase (JAK) inhibitors are in early clinical development.
Caveats and uncertainty
- Most RCTs have relatively short follow-up durations (12-24 weeks), limiting understanding of long-term efficacy and safety.
- Patient populations in trials often exclude those with severe organ involvement or multiple comorbidities, which may limit generalizability.
- Head-to-head comparisons between agents are scarce, complicating treatment selection.
- Adverse effects such as liver enzyme elevations with ERAs, hypotension with PDE5i, and infusion-related reactions with prostacyclin analogs require careful monitoring.
- The role of combination therapy versus monotherapy remains to be fully elucidated.
- Data on newer biologics and small molecules are preliminary and should be interpreted as hypothesis-generating.
How this may change practice
Clinicians managing SSc patients with digital ulcers should consider early initiation of ERAs or PDE5 inhibitors to reduce new ulcer formation and promote healing, especially in patients with recurrent or multiple ulcers. Intravenous prostacyclin analogs remain important for severe cases or those refractory to oral agents. Emerging therapies may offer future options but currently warrant use within clinical trials. Multidisciplinary care including wound management and pain control remains essential. Regular monitoring for adverse events and individualized treatment adjustments are critical to optimize outcomes.